2. Search Result
Search Result
Pathways Recommended: Immunology/Inflammation
Results for "

Cancer immunology

" in MedChemExpress (MCE) Product Catalog:

2753

Inhibitors & Agonists

2

Screening Libraries

15

Fluorescent Dye

29

Biochemical Assay Reagents

96

Peptides

130

Inhibitory Antibodies

1076

Natural
Products

196

Isotope-Labeled Compounds

12

Click Chemistry

35

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131967
    CD73-IN-4

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD73-IN-4
  • HY-156569
    DGKα-IN-2

    		DGK Inflammation/Immunology Cancer
    DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-2
  • HY-78131C
    Ibuprofen sodium
    10+ Cited Publications

    (±)-Ibuprofen sodium

    		 COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen sodium
  • HY-78131
    Ibuprofen
    10+ Cited Publications

    (±)-Ibuprofen

    		 COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen
  • HY-100586
    Ibuprofen L-lysine
    10+ Cited Publications

    (±)-Ibuprofen L-lysine

    		 COX Apoptosis Parasite Infection Inflammation/Immunology Cancer
    Ibuprofen ((±)-Ibuprofen) L-lysine is a potent orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen L-lysine inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen L-lysine is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen L-lysine can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen L-lysine
  • HY-78131S2
    Ibuprofen-d4

    		Apoptosis COX Parasite Cancer
    Ibuprofen-d4 is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[2][3][4][5].
    Ibuprofen-d4
  • HY-147283
    MK2-IN-4

    		MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC50 value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .
    MK2-IN-4
  • HY-156570
    DGKα-IN-3

    		DGK Inflammation/Immunology Cancer
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-149411
    IDO1/TDO-IN-6

    		Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    IDO1/TDO-IN-6 (compound 11) is a dual inhibitor of IDO1/TDO with IC50s of 2.25 and 2.89 μM, respectively. IDO1/TDO-IN-6 has inhibitory effects on IDO1 and TDO, with Ki values of 1.9 and 3.1 μM, respectively. IDO1/TDO-IN-6 can be used in cancer and immunology research .
    IDO1/TDO-IN-6
  • HY-78131R
    Ibuprofen (Standard)

    		COX Apoptosis Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Ibuprofen (Standard) is the analytical standard of Ibuprofen. This product is intended for research and analytical applications. Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen (Standard)
  • HY-P9902
    Pembrolizumab
    10+ Cited Publications

    MK-3475; Lambrolizumab

    		 PD-1/PD-L1 Cancer
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    Pembrolizumab
  • HY-156571
    DGKα-IN-4

    		DGK Cancer
    DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
    DGKα-IN-4
  • HY-135890
    CG347B
    2 Publications Verification

    		 HDAC Neurological Disease Inflammation/Immunology Cancer
    CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research .
    CG347B
  • HY-78131S3
    Ibuprofen-13C6

    (±)-Ibuprofen-13C6

    		 Isotope-Labeled Compounds Cancer
    Ibuprofen- 13C6 ((±)-Ibuprofen- 13C6) is a 13C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .
    Ibuprofen-13C6
  • HY-156415
    NLRP3 agonist 2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3 agonist 2 (compound 22) is a orally active NLRP3 agonist.NLRP3 agonist 2 activates Caspase-1 in THP1 cells .
    NLRP3 agonist 2
  • HY-151093
    IDO2-IN-1
    1 Publications Verification

    		 Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology
    IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research .
    IDO2-IN-1
  • HY-153245
    JNJ-64264681

    		Btk Inflammation/Immunology Cancer
    JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 exhibits good pharmacokinetic characteristics and can be used for cancer and autoimmune diseases research .
    JNJ-64264681
  • HY-149992
    MyD88-IN-1

    		MyD88 Inflammation/Immunology Cancer
    MyD88-IN-1 is a potent MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory .
    MyD88-IN-1
  • HY-154869
    PD-1/PD-L1-IN-34

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .
    PD-1/PD-L1-IN-34
  • HY-P10218A
    MANS peptide TFA

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P10218
    MANS peptide

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-E70302
    ST8 alpha-2,8-Sialyltransferase 6

    ST8SIA6

    		 Endogenous Metabolite Inflammation/Immunology Cancer
    ST8 alpha-2,8-Sialyltransferase 6 (ST8SIA6) is a sialyltransferase that generates α2,8-linked disialic acids, which bind to mouse Siglec-E and human Siglec-7 and -9, and accelerates tumor growth by suppressing anti-tumor immune responses .
    ST8 alpha-2,8-Sialyltransferase 6
  • HY-152120
    (±)-Aiphanol

    Aiphanol

    		 COX VEGFR Inflammation/Immunology Cancer
    (±)-Aiphanol is a newly discovered stilbenolignan analog. (±)-Aiphanol exhibits significant anti-inflammatory activity, acting through inhibition of COX-1 and COX-2. The inhibitory effect on COX-1 (IC50 = 1.9 μM) is particularly strong, while the effect on COX-2 (IC50= 9.9 μM) is relatively weak .(±)-Aiphanol effectively inhibits VEGFR2 (IC50=0.92 µM). (±)-Aiphanol blocks angiogenesis and promotes apoptosis through inhibition of VEGFR2 and COX2 activity. (±)-Aiphanol is orally active .
    (±)-Aiphanol
  • HY-158045
    PROTAC PARP1 degrader-1

    		PROTACs PARP Inflammation/Immunology Cancer
    PROTAC PARP1 degrader-1 (Compound CN0) is a PROTAC degrader of PARP1. PROTAC PARP1 degrader-1 activates the cGAS/STING immunity pathway and eventually enhances T cell killing of tumor cells. PROTAC PARP1 degrader-1 inhibits DNA damage repair, resulting in highly efficient accumulation of cytosolic DNA fragments (Blue: CRBN ligand, Black: linker; Pink: PARP1 inhibitor) .
    PROTAC PARP1 degrader-1
  • HY-162425
    Anti-inflammatory agent 78

    		PGE synthase COX Inflammation/Immunology Cancer
    Anti-inflammatory agent 78 (compound L-37) is a potent anti-inflammatory agent. Anti-inflammatory agent 78 has significant potency on PGE2, PGE1, COX-2 and COX-1 inhibition. Anti-inflammatory agent 78 can inhibits NO release in LPS-stimulated RAW 264.7 cell line .
    Anti-inflammatory agent 78
  • HY-158169
    AhR agonist 7

    		Aryl Hydrocarbon Receptor Inflammation/Immunology Cancer
    AhR agonist 7 (Compound 8) has a good activation activity against AhR (ECsub>50 = 13nM) .
    AhR agonist 7
  • HY-158205
    HPO-DAEE

    4-Hydroperoxy-2-decenoic acid ethyl ester

    		 Reactive Oxygen Species HDAC SOD Inflammation/Immunology Cancer
    HPO-DAEE (4-Hydroperoxy-2-decenoic acid ethyl ester) elicits nuclear accumulation of Nrf2 and activated antioxidant response element (ARE). HPO-DAEE induces antioxidant genes upregulation (eg: HO-1) through Nrf2-ARE signaling. HPO-DAEE induces reactive oxygen species generation. HPO-DAEE also inhibits histone deacetylase and upregulate expression of extracellular superoxide dismutase via histone acetylation. HPO-DAEE protects against 6-hydroxydopamine-induced cell death via activation of Nrf2-ARE and eIF2α-ATF4 pathways .
    HPO-DAEE
  • HY-163428
    ZN-A-1041

    		EGFR Inflammation/Immunology Cancer
    ZN-A-1041 inhibits HER2 in BT474 cell and wt-EGFR in H838 cells, with IC50s of 9.5 nM and 12 μM respectively. ZN-A-1041 can be used for research of cancer and inflammation .
    ZN-A-1041
  • HY-162482
    EGFR kinase inhibitor 5

    		EGFR Apoptosis Inflammation/Immunology Cancer
    EGFR kinase inhibitor 5 (Compound 4c) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 18.35 μM. EGFR kinase inhibitor 5 induces apoptosis. EGFR kinase inhibitor 5 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg) .
    EGFR kinase inhibitor 5
  • HY-162483
    EGFR kinase inhibitor 6

    		EGFR Apoptosis Inflammation/Immunology Cancer
    EGFR kinase inhibitor 6 (Compound 4b) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 24.34 μM. EGFR kinase inhibitor 6 induces apoptosis. EGFR kinase inhibitor 6 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg) .
    EGFR kinase inhibitor 6
  • HY-163535
    J208

    		HDAC DNA Methyltransferase Apoptosis Inflammation/Immunology Cancer
    J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .
    J208
  • HY-163495
    HPK1-IN-44

    		MAP4K Inflammation/Immunology Cancer
    HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 (IC50=0.1 nM (40 μM ATP)) .
    HPK1-IN-44
  • HY-132130
    BRD4 Inhibitor-13

    		Epigenetic Reader Domain Inflammation/Immunology Cancer
    BRD4 Inhibitor-13 (Compound 2) is a BRD4 ligand, and can be used for research of cancer, inflammation.
    BRD4 Inhibitor-13
  • HY-160896
    Autophagy-IN-5

    		Autophagy Inflammation/Immunology Cancer
    Autophagy-IN-5 (Compound A9) is an inhibitor for autophagy with an EC50 of 0.736 μM .
    Autophagy-IN-5
  • HY-P10375
    BMS-986189

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-986189 is a macrocyclic peptide inhibitor of PD-L1 (IC50: 1.03 nM), and can be used for cancer research .
    BMS-986189
  • HY-N12817
    Anti-inflammatory agent 80

    		NO Synthase Inflammation/Immunology Cancer
    Anti-inflammatory agent 80 (Compound 2/2f) is an anti-inflammatory agent and has anti-tumor activity. Anti-inflammatory agent 80 can be isolated fromCynanchum limprichtiiSchltr .
    Anti-inflammatory agent 80
  • HY-156920
    VDX-111

    		Necroptosis RIP kinase Inflammation/Immunology Cancer
    VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model .
    VDX-111
  • HY-119866
    β-Alethine

    		TNF Receptor Apoptosis Inflammation/Immunology Cancer
    β-Alethine is a disulfide that can be used as an anti-tumor agent and immune adjuvant .
    β-Alethine
  • HY-101664R
    Ilaprazole (Standard)

    		Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (Standard) is the analytical standard of Ilaprazole. This product is intended for research and analytical applications. Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole (Standard)
  • HY-10343R
    Sotrastaurin (Standard)

    		PKC Inflammation/Immunology Cancer
    Sotrastaurin (Standard) is the analytical standard of Sotrastaurin. This product is intended for research and analytical applications. Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .
    Sotrastaurin (Standard)
  • HY-12100R
    Umeclidinium bromide (Standard)

    		mAChR Inflammation/Immunology Cancer
    Umeclidinium (bromide) (Standard) is the analytical standard of Umeclidinium (bromide). This product is intended for research and analytical applications. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
    Umeclidinium bromide (Standard)
  • HY-12887R
    Piclamilast (Standard)

    		Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Piclamilast (Standard) is the analytical standard of Piclamilast. This product is intended for research and analytical applications. Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively .
    Piclamilast (Standard)
  • HY-13038AR
    Fostamatinib (Standard)

    		Syk FLT3 Inflammation/Immunology Cancer
    Fostamatinib (Standard) is the analytical standard of Fostamatinib. This product is intended for research and analytical applications. Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
    Fostamatinib (Standard)
  • HY-13463R
    Avatrombopag (Standard)

    		Thrombopoietin Receptor Inflammation/Immunology Cancer
    Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag (Standard)
  • HY-13662BR
    (R)-Lansoprazole (Standard)

    		Proton Pump Inflammation/Immunology Cancer
    (R)-Lansoprazole (Standard) is the analytical standard of (R)-Lansoprazole. This product is intended for research and analytical applications. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    (R)-Lansoprazole (Standard)
  • HY-145453R
    Propacetamol (Standard)

    		Others Inflammation/Immunology Cancer
    Propacetamol (Standard) is the analytical standard of Propacetamol. This product is intended for research and analytical applications. Propacetamol is an analgesic agent. Propacetamol also is a precursor form of paracetamol. Propacetamol can be used in postoperative pain, acute trauma and gastrointestinal disorders .
    Propacetamol (Standard)
  • HY-14658R
    Thalidomide (Standard)

    		Ligands for E3 Ligase Autophagy Apoptosis Inflammation/Immunology Cancer
    Thalidomide (Standard) is the analytical standard of Thalidomide. This product is intended for research and analytical applications. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.
    Thalidomide (Standard)
  • HY-15388R
    Tazarotene (Standard)

    		RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (Standard) is the analytical standard of Tazarotene. This product is intended for research and analytical applications. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene (Standard)
  • HY-15689R
    Epacadostat (Standard)

    		Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    Epacadostat (Standard) is the analytical standard of Epacadostat. This product is intended for research and analytical applications. Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM .
    Epacadostat (Standard)
  • HY-15762R
    Valdecoxib (Standard)

    		COX Endogenous Metabolite Inflammation/Immunology Cancer
    Valdecoxib (Standard) is the analytical standard of Valdecoxib. This product is intended for research and analytical applications. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
    Valdecoxib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: